| Caitlin Hespe, OTR/L | |
|
1124 Washington Blvd, Newcastle, WY 82701-2972 | |
| (307) 746-3720 | |
| (307) 746-3723 |
| Full Name | Caitlin Hespe |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 1124 Washington Blvd, Newcastle, Wyoming |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073942132 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OTR-1021 (Wyoming) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Caitlin Hespe, OTR/L 1124 Washington Blvd, Newcastle, WY 82701-2972 Ph: (307) 746-3720 | Caitlin Hespe, OTR/L 1124 Washington Blvd, Newcastle, WY 82701-2972 Ph: (307) 746-3720 |
News Archive
The National Institutes of Health has awarded a five-year, $28 million grant to establish a new center for excellence to find an antibody "cocktail" to fight two types of viruses that cause severe hemorrhagic fever, including the deadly Ebola virus. The project involves researchers from 15 institutions, including Kartik Chandran, Ph.D., and Jonathan Lai, Ph.D., at Albert Einstein College of Medicine of Yeshiva University. Einstein will receive approximately $4 million of the total grant.
For women undergoing breast reconstruction using the advanced "DIEP" technique, a simple formula can reliably tell whether there will be sufficient blood flow to nourish the DIEP flap, reports a paper in Plastic and Reconstructive Surgery—Global Open®, the official open-access medical journal of the American Society of Plastic Surgeons (ASPS).
A non-invasive test that includes detection of the genetic abnormalities related to cancer could significantly improve the effectiveness of colon cancer screening, according to research published by a team of scientists including David Ransohoff, MD, professor of medicine at the UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center member.
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS).
Inhibitex, Inc. today reported top-line safety and efficacy data from its Phase II clinical trial of FV-100, an oral antiviral compound being developed to treat herpes zoster, more commonly referred to as shingles. The study was the first clinical trial to assess the antiviral activity of FV-100, included 350 shingles patients and compared two once-daily doses of FV-100 (200 mg and 400 mg) to an active control, valacyclovir, one of the most commonly-used antiviral drugs to treat shingles.
› Verified 9 days ago
Michalyn Trimble, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 104 Stampede St, Newcastle, WY 82701 Phone: 307-746-4560 | |
Nathina Crabtree, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 104 Stampede St, Newcastle, WY 82701 Phone: 307-746-4560 | |
Ms. Terri Gassman, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1124 Washington Blvd, Newcastle, WY 82701 Phone: 307-746-3720 Fax: 307-746-3723 |